A new series of therapeutic modalities resulting in degradation of target proteins, termed
proteolysis targeting chimeras (PROTACs), hold significant therapeutic potential with …

Targeted protein degradation using Proteolysis Targeting Chimeras (PROTACs) has
emerged as a novel therapeutic modality in drug discovery. PROTACs mediate the …

Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into
the proximity of proteins of interest, inducing ubiquitination-dependent degradation. A major …

Molecular glues and bivalent inducers of protein degradation (also known as PROTACs)
represent a fascinating new modality in pharmacotherapeutics: the potential to knockdown …

Abstract Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted
proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic …

Pharmacological control of the ubiquitin-proteasome system (UPS) is of intense interest in
drug discovery. Here, we report the development of chemical inhibitors of the ubiquitin …

Targeted protein degradation with molecular glue degraders has arisen as a powerful
therapeutic modality for eliminating classically undruggable disease-causing proteins …

The current predominant therapeutic paradigm is based on maximizing drug-receptor
occupancy to achieve clinical benefit. This strategy, however, generally requires excessive …

Proteolysis targeting chimeras (PROTACs) represent a new class of promising therapeutic
modalities. PROTACs hijack E3 ligases and the ubiquitin-proteasome system (UPS), leading …

Traditionally, biological probes and drugs have targeted the activities of proteins (such as
enzymes and receptors) that can be readily controlled by small molecules. The remaining …